Taken together, the significant in vivo efficacy of VIS832 in the MM1S xenograft murine model, coupled with its mechanisms of action and in vitro MM cytotoxicity, both confirm CD138 as a promising MM target and provide the basis for clinical development of VIS832 as a potentially effective mAb-based immunotherapy. Here, SDC1 is linked to Miyoshi myopathy.